14-3-3σ Positively Regulates p53 and Suppresses Tumor Growth
Authors:
- 1 October 2003
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 23 (20) , 7096-7107
Abstract
The 14-3-3σ (sigma) protein, a negative regulator of the cell cycle, is a human mammary epithelium-specific marker that is downregulated in transformed mammary carcinoma cells. It has also been identified as a p53-inducible gene product involved in cell cycle checkpoint control after DNA damage. Although 14-3-3σ is linked to p53-regulated cell cycle checkpoint control, detailed mechanisms of how cell cycle regulation occurs remain unclear. Decreased expression of 14-3-3σ was recently reported in several types of carcinomas, further suggesting that the negative regulatory role of 14-3-3σ in the cell cycle is compromised during tumorigenesis. However, this possible tumor-suppressive role of 14-3-3σ has not yet been characterized. Here, we studied the link between 14-3-3σ activities and p53 regulation. We found that 14-3-3σ interacted with p53 in response to the DNA-damaging agent adriamycin. Importantly, 14-3-3σ expression led to stabilized expression of p53. In studying the molecular mechanism of this increased stabilization of p53, we found that 14-3-3σ antagonized the biological functions of Mdm2 by blocking Mdm2-mediated p53 ubiquitination and nuclear export. In addition, we found that 14-3-3σ facilitated the oligomerization of p53 and enhanced p539s transcriptional activity. As a target gene of p53, 14-3-3σ appears to have a positive feedback effect on p53 activity. Significantly, we also showed that overexpression of 14-3-3σ inhibited oncogene-activated tumorigenicity in a tetracycline-regulated 14-3-3σ system. These results defined an important p53 regulatory loop and suggested that 14-3-3σ expression can be considered for therapeutic intervention in cancers.Keywords
This publication has 49 references indexed in Scilit:
- Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2Oncogene, 2002
- p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesisOncogene, 2001
- p53 as a drug target in cancer therapyExpert Opinion on Therapeutic Patents, 2001
- MdmX Binding to ARF Affects Mdm2 Protein Stability and p53 TransactivationJournal of Biological Chemistry, 2001
- An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivoOncogene, 2000
- Specific Interactions with TBP and TFIIB in Vitro Suggest That 14-3-3 Proteins May Participate in the Regulation of Transcription When Part of a DNA Binding ComplexThe Plant Cell, 1999
- Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.Proceedings of the National Academy of Sciences, 1996
- Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridizationGene, 1995
- Isoforms of 14‐3‐3 protein can form homo‐ and heterodimers in vivo and in vitro: implications for function as adapter proteinsFEBS Letters, 1995
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989